CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$4.67−0.15 (-3.11%)
Close on Nov 17, 2026Market cap $364.00MP/E –Yield –
CorMedix price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
CorMedix's price to sales ratio was 0.9× on Nov 11, 2026, against 3.6× a year earlier. Over the last 3 years it ranged from 0.9× to 478.8×, with a median of 10.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.9× | −3.4 |
| 2025 | Dec 31, 2025 | 4.3× | −371.8 |
| 2020 | Apr 30, 2020 | 376.0× | +153.7 |
| 2019 | Oct 31, 2019 | 222.3× | −91.3 |
| 2018 | Jun 29, 2018 | 313.6× | – |
See a number that looks wrong?